| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 24024 |
| Drug | Tirzepatide |
| Brand | (Mounjaro®) |
| Indication | For chronic weight management, including weight loss and weight maintenance, in adults with an initial body mass index of: ≥30 kg/m2, or ≥27 kg/m2 to <30 kg/m2 in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). |
| Assessment Process | |
| Rapid review commissioned | 24/06/2024 |
| Rapid review completed | 30/07/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical and cost effectiveness of tirzepatide for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/08/2024 |
| Pre-submission consultation with Applicant | 15/10/2024 |
